CCl4-Induced Liver Fibrosis Model: Protocols, Timelines, vs MASH Diet Models
A comprehensive guide on the carbon tetrachloride (CCl4) liver fibrosis model—the gold standard for pure anti-fibrotic drug screening. Learn protocols, typical staging (F1-F3), and when to choose this over MASH diet models.
Introduction: Why the CCl4 Model Remains the "Gold Standard"
The Carbon Tetrachloride (CCl4)-induced liver injury model is the oldest and most widely utilized preclinical animal model in liver fibrosis and cirrhosis research worldwide. While "dietary models" like high-fat or GAN diets have taken the spotlight recently due to the focus on NASH/MASH pathophysiology, the CCl4 model remains the undisputed gold standard for studying the pure "fibrogenic process" itself and for screening direct anti-fibrotic drugs.
This article details the specific protocols, the timeline of histological changes, and the appropriate selection between the CCl4 model and MASH models—vital information for both researchers and those outsourcing to a CRO.
1. Mechanism of CCl4-Induced Fibrosis
Carbon tetrachloride itself is not highly toxic; rather, it is metabolized by the cytochrome P450 system (primarily CYP2E1) in hepatocytes to generate the highly reactive trichloromethyl radical (CCl3•).
- Radical Production & Lipid Peroxidation: CCl3• reacts with polyunsaturated fatty acids in cell membranes, initiating a chain reaction of lipid peroxidation.
- Hepatocellular Necrosis: Cell and organelle membranes are destroyed, leading to centrilobular hepatocyte necrosis.
- Kupffer Cell Activation: Damage-Associated Molecular Patterns (DAMPs) released from necrotic tissue activate resident liver macrophages (Kupffer cells), triggering the release of cytokines like TNF-α and TGF-β.
- Hepatic Stellate Cell (HSC) Activation: Persistent TGF-β stimulation drives HSCs (vitamin A-storing cells) to transdifferentiate into myofibroblasts. These activated cells overproduce collagen (Type I, III), propelling fibrosis.
2. Standard Protocols and Administration Routes
CCl4 is typically administered diluted in a vehicle such as olive oil or corn oil (e.g., 10–25% v/v). Common administration routes in mice and rats include:
Intraperitoneal Injection (i.p.)
- Pros: Accurate dose control, offering rapid and robust induction of liver injury.
- Cons: Risk of ascites and visceral adhesions, which can lower survival rates during long-term chronic dosing.
- Standard Regimen: Administered 2 to 3 times per week at a dose of 0.5–1.0 mL/kg CCl4 (based on total diluted volume).
Oral Gavage (p.o.)
- Pros: No risk of intraperitoneal adhesions; better mimics actual oral toxicant ingestion. Suitable for long-term (8–12+ weeks) administration.
- Cons: Absorption can vary based on stomach contents, leading to higher inter-individual variability in fibrosis levels.
Inhalation
- Pros: Non-invasive and allows for batch processing of multiple animals.
- Cons: Requires specialized chambers and exhaust systems; precise control of the inhaled dose per animal is difficult.
[!TIP] When Outsourcing to a CRO: If the primary goal is drug efficacy testing, the "Intraperitoneal (i.p.) twice-weekly" model (usually lasting 4 or 6 weeks) is the most frequently adopted due to its low variability and high reproducibility.
3. Timeline of Fibrosis Progression (Mouse, Twice-Weekly i.p.)
Under chronic CCl4 administration, the liver undergoes sequential pathological changes:
- 1–2 Weeks (Early Stage / F1 Equivalent): Severe initial hepatocyte necrosis and substantial inflammation (macrophage infiltration). ALT/AST levels spike dramatically. Collagen deposition is mild and strictly localized around the central veins.
- 3–4 Weeks (Progressive Stage / F2 Equivalent): Bridging fibrosis begins to form. Fibrotic septa stretch to connect central veins to each other (C-C) or central veins to portal tracts (C-P). This is the standard evaluation window for testing anti-fibrotic agents (e.g., a 4-week model with concurrent drug administration).
- 6–8 Weeks (Severe Fibrosis / F3 Equivalent): Thick fibrotic bands completely surround hepatic lobules with advanced bridging fibrosis. Since reaching full cirrhosis with definitive pseudolobules (F4) requires substantially longer administration, this stage is typically evaluated as severe F3-equivalent fibrosis. It may be accompanied by portal hypertension.
Utilization as a Resolution Model: If CCl4 is halted at 4 weeks and animals are rested for several weeks thereafter, the fibrosis will naturally regress (via macrophage-driven collagen degradation). Studying intervention targets (such as manipulating M2 macrophage function) during this "resolution phase" is a powerful drug discovery paradigm.
4. CCl4 Model vs. MASH (Dietary) Models
Choosing between the CCl4 model and MASH models (like GAN or CDAHFD diets) is a critical junction in any drug discovery project.
| Feature | CCl4 Model | MASH Diet Model (e.g., GAN Diet) |
|---|---|---|
| Primary Driver of Disease | Direct chemical toxicity & sterile inflammation | Lipotoxicity, metabolic dysfunction, insulin resistance |
| Steatosis (Fatty Liver) | Absent or extremely mild | Pronounced (macrovesicular steatosis, etc.) |
| Induction Period | 4–6 weeks (Very rapid) | 12–24+ weeks (Slow) |
| Fibrosis Severity & Uniformity | Severe (can reach F3), low inter-individual variability | Mild to moderate (mostly F2), higher individual variation |
| Recommended Target Profile | Direct HSC inhibitors, TGF-β blockade, collagen degradation promoters | Lipid metabolism improvers, metabolic hormones (GLP-1), anti-oxidants |
Conclusion: When to choose CCl4?
If your drug candidate represents a "pure anti-fibrotic" (e.g., directly blocking HSC collagen production), the CCl4 model is the absolute first choice. It eliminates the confounding variables of metabolic pathways and yields clear, quantifiable results (via Sirius Red morphometry) in a fraction of the time. Conversely, if the drug mitigates fibrosis indirectly via weight loss or metabolic repair (like GLP-1 receptor agonists or THR-β agonists), investing in the slower MASH diet models is mandatory.
5. Key Evaluation Endpoints
Efficacy endpoints in a CCl4 study typically involve a combination of the following:
- Histopathology (The Core Element): Automated image quantification (e.g., via ImageJ) of fibrosis area using Sirius Red or Masson's Trichrome staining.
- Blood Biochemistry: Serum ALT and AST (markers of liver injury). Since these spike immediately post-dosing, careful timing for blood collection is required.
- Gene/Protein Expression:
Col1a1,Col3a1(Collagen production)Acta2(α-SMA: Myofibroblast marker)Tgfb1(Major profibrotic cytokine)Timp1(Inhibitor of matrix degradation)
- Absolute Biochemical Quantification: Measuring total collagen via the Hydroxyproline assay (using kits or HPLC) from liver tissue extracts.
Summary
Due to its high reproducibility and capacity to rapidly induce robust fibrosis, the CCl4-induced liver injury model serves as the crucial gatekeeper for anti-fibrotic drug development. Success hinges on selecting the appropriate dosing duration and establishing a robust pathological evaluation framework that pairs Sirius Red quantitative imaging with absolute hydroxyproline measurement.